Teradyne Inc. Stock Sheds 13.3%, Underperforms Peers
Dow Jones2026/09/14 20:32This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Teradyne Inc. tumbled 13.3% to $329.20 on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.5% to 7,619.98 and Dow Jones Industrial Average falling 0.3% to 52,421.20.
Teradyne Inc. closed 32.5% below its 52-week high of $487.91, which the company achieved on June 30th.
The stock underperformed when compared to some of its peers, as Keysight Technologies Inc. fell 7.0% to $314.96, Fortive Corp. rose 0.9% to $55.19, and Cohu Inc. fell 12.46% to $49.97.
Trading volume totaled 4.9 million, compared to the 50-day average of 3.1 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 14, 2026 16:32 ET (20:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
Crypto prices
More
